Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Pipeline Review, H2 2018
Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Pipeline Review, H2 2018
SUMMARY
Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta - Pipeline Review, H2 2018, outlays comprehensive information on the Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Inhibitor of nuclear factor kappa-B kinase subunit beta is a protein encoded by the IKBKB gene. It plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. It acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues.
Free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis. The molecules developed by companies in Preclinical stages are 6 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Gastrointestinal and Metabolic Disorders which include indications Glioblastoma Multiforme (GBM), Inflammation, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Colorectal Cancer, Diabetic Retinopathy, Inflammatory Bowel Disease, Mantle Cell Lymphoma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Solid Tumor and Squamous Cell Carcinoma.
Furthermore, this report also reviews key players involved in Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta - Pipeline Review, H2 2018, outlays comprehensive information on the Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Inhibitor of nuclear factor kappa-B kinase subunit beta is a protein encoded by the IKBKB gene. It plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. It acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues.
Free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis. The molecules developed by companies in Preclinical stages are 6 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Gastrointestinal and Metabolic Disorders which include indications Glioblastoma Multiforme (GBM), Inflammation, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Colorectal Cancer, Diabetic Retinopathy, Inflammatory Bowel Disease, Mantle Cell Lymphoma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Solid Tumor and Squamous Cell Carcinoma.
Furthermore, this report also reviews key players involved in Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10)
- The report reviews Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) targeted therapeutics and enlists all their major and minor projects
- The report assesses Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Overview
Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Companies Involved in Therapeutics Development
EntreChem SL
IMMD Inc
Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Drug Profiles
13-197 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EC-70124 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMD-0354 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMD-0560 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMD-2560 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IKBKB for Inflammation and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IKKb for Glioblastoma Multiforme - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TLX-1423 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Dormant Products
Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Discontinued Products
Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Product Development Milestones
Featured News & Press Releases
Jan 17, 2018: EntreChem reports potent activity of EC-70124 in Acute Myeloid Leukemia
Mar 10, 2016: EntreChem's orally active EC-70124 reverts tumorigenic and stem cell properties in prostate cancer
Dec 21, 2015: New EntreChem publication in Oncotarget describing activity of EC-70124 in colorectal cancer
Sep 26, 2014: EntreChem presents in ESMO 2014 congress: Activity of the multi-targeted kinase inhibitor EC-70124 in colorectal cancer
Jun 02, 2014: EntreChem presents in 2014 ASCO Annual Meeting: Activity of the multi-targeted kinase inhibitor EC-70124 in Triple Negative Breast Cancer
Apr 30, 2013: Entrechem Announces Presentation Of Positive Preclinical Results Of Orally Active Kinase Inhibitor EC-70124 At 2013 AACR Annual Meeting
Mar 26, 2012: EntreChem's Kinase Inhibitor Shows Potential For Treatment Of Head And Neck Cancer
May 09, 2011: EntreChem's Developmental Drug EC-70124 Creates New Strategy For Treatment Of Glioblastoma
Feb 15, 2009: IMMD Completes Phase I Clinical Trial Of IMD-2560 In UK
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Overview
Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Companies Involved in Therapeutics Development
EntreChem SL
IMMD Inc
Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Drug Profiles
13-197 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EC-70124 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMD-0354 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMD-0560 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMD-2560 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IKBKB for Inflammation and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IKKb for Glioblastoma Multiforme - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TLX-1423 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Dormant Products
Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Discontinued Products
Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Product Development Milestones
Featured News & Press Releases
Jan 17, 2018: EntreChem reports potent activity of EC-70124 in Acute Myeloid Leukemia
Mar 10, 2016: EntreChem's orally active EC-70124 reverts tumorigenic and stem cell properties in prostate cancer
Dec 21, 2015: New EntreChem publication in Oncotarget describing activity of EC-70124 in colorectal cancer
Sep 26, 2014: EntreChem presents in ESMO 2014 congress: Activity of the multi-targeted kinase inhibitor EC-70124 in colorectal cancer
Jun 02, 2014: EntreChem presents in 2014 ASCO Annual Meeting: Activity of the multi-targeted kinase inhibitor EC-70124 in Triple Negative Breast Cancer
Apr 30, 2013: Entrechem Announces Presentation Of Positive Preclinical Results Of Orally Active Kinase Inhibitor EC-70124 At 2013 AACR Annual Meeting
Mar 26, 2012: EntreChem's Kinase Inhibitor Shows Potential For Treatment Of Head And Neck Cancer
May 09, 2011: EntreChem's Developmental Drug EC-70124 Creates New Strategy For Treatment Of Glioblastoma
Feb 15, 2009: IMMD Completes Phase I Clinical Trial Of IMD-2560 In UK
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by EntreChem SL, H2 2018
Pipeline by IMMD Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by EntreChem SL, H2 2018
Pipeline by IMMD Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
EntreChem SL
IMMD Inc
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
EntreChem SL
IMMD Inc
